Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study
- PMID: 30448517
- DOI: 10.1016/j.jcrc.2018.11.003
Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study
Abstract
Background: The aim of this proof of concept, prospective, randomized pilot trial was to investigate the effects of extracorporeal cytokine removal (CytoSorb®) applied as a standalone treatment in patients with septic shock.
Methods: 20 patients with early (<24 h) onset of septic shock of medical origin, on mechanical ventilation, norepinephrine>10 μg/min, procalcitonin (PCT) > 3 ng/mL without the need for renal replacement therapy were randomized into CytoSorb (n = 10) and Control groups (n = 10). CytoSorb therapy lasted for 24 h. Clinical and laboratory data were recorded at baseline (T0), T12, T24, and T48 hours.
Results: Overall SOFA scores did not differ between the groups. In the CytoSorb-group norepinephrine requirements and PCT concentration decreased significantly (norepinephrine: CytoSorb: T0 = 0.54[IQR:0.20-1.22], T48 = 0.16[IQR:0.07-0.48], p = .016; Controls: T0 = 0.43[IQR:0.19-0.64], T48 = 0.25[IQR:0.08-0.65] μg/kg/min; PCT: CytoSorb: T0 median = 20.6[IQR: 6.5-144.5], T48 = 5.6[1.9-54.4], p = .004; Control: T0 = 13.2[7.6-47.8], T48 = 9.2[3.8-44.2]ng/mL). Big-endothelin-1 concentrations were also significantly lower in the CytoSorb group (CytoSorb: T0 = 1.3 ± 0.6, *T24 = 1.0 ± 0.4, T48 = 1.4 ± 0.8, *p = .003; Control: T0 = 1.1 ± 0.7, T24 = 1.1 ± 0.6, T48 = 1.2 ± 0.6 pmol/L, p = .115). There were no CytoSorb therapy-related adverse events.
Conclusions: This is the first trial to investigate the effects of early extracorporeal cytokine adsorption treatment in septic shock applied without renal replacement therapy. It was found to be safe with significant effects on norepinephrine requirements, PCT and Big-endothelin-1 concentrations compared to controls.
Trial registration: The study has been registered on ClinicalTrials.gov, under the registration number of NCT02288975, registered 13 November 2014.
Keywords: CytoSorb; Cytokine removal; Cytokine storm; Extracorporeal blood purification; Hemoadsorption; Septic shock.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Hemoperfusion with Cytosorb in pediatric patients with septic shock: A retrospective observational study.Int J Artif Organs. 2020 Sep;43(9):587-593. doi: 10.1177/0391398820902469. Epub 2020 Jan 31. Int J Artif Organs. 2020. PMID: 32003289
-
Hemoadsorption by extracorporeal cytokine adsorption therapy (CytoSorb®) in the management of septic shock: A retrospective observational study.Int J Artif Organs. 2020 Jun;43(6):372-378. doi: 10.1177/0391398819891739. Epub 2019 Dec 23. Int J Artif Organs. 2020. PMID: 31868078
-
Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study.J Artif Organs. 2017 Sep;20(3):252-259. doi: 10.1007/s10047-017-0967-4. Epub 2017 Jun 6. J Artif Organs. 2017. PMID: 28589286 Clinical Trial.
-
Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review.Blood Purif. 2018;46(4):337-349. doi: 10.1159/000492379. Epub 2018 Sep 3. Blood Purif. 2018. PMID: 30176653 Review.
-
Renal Replacement Techniques in Septic Shock.Int J Mol Sci. 2021 Sep 23;22(19):10238. doi: 10.3390/ijms221910238. Int J Mol Sci. 2021. PMID: 34638575 Free PMC article. Review.
Cited by
-
Hemoadsorption therapy in the critically ill: solid base but clinical haze.Ann Intensive Care. 2019 Jan 31;9(1):22. doi: 10.1186/s13613-019-0491-1. Ann Intensive Care. 2019. PMID: 30706173 Free PMC article. No abstract available.
-
Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series.J Med Case Rep. 2021 Sep 18;15(1):476. doi: 10.1186/s13256-021-03021-y. J Med Case Rep. 2021. PMID: 34535189 Free PMC article.
-
Extracorporeal blood purification benefits in post-caesarean patient with severe acute respiratory distress syndrome due to miliary tuberculosis: a case report.J Med Case Rep. 2023 Apr 12;17(1):157. doi: 10.1186/s13256-023-03853-w. J Med Case Rep. 2023. PMID: 37041589 Free PMC article.
-
Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb®) in patients with sepsis and septic shock.World J Crit Care Med. 2021 Jan 9;10(1):22-34. doi: 10.5492/wjccm.v10.i1.22. eCollection 2021 Jan 9. World J Crit Care Med. 2021. PMID: 33505870 Free PMC article.
-
Endothelial Protection and Improved Micro- and Macrocirculation with Hemoadsorption in Critically Ill Patients.J Clin Med. 2024 Nov 22;13(23):7044. doi: 10.3390/jcm13237044. J Clin Med. 2024. PMID: 39685503 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical